RxDoctor Payments DataLook up a doctor →

Paul Volansky, DO

Internal Medicine · Corinth, MSNPI 1588006043

Payments from drug & device makers

$14,884in general payments, 2019–2025

Across 455 payments — averaging $32.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$3K
  • Boston Scientific$2K
  • Medtronic$1K
  • Biotronik Inc.$1K
  • Penumbra, Inc.$909
  • AstraZeneca$835
  • plus $6K from 40 others

What the payments were for

  • Travel & lodging$2,90720%
  • Food & beverage$11,86480%
  • Education$1131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,884 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$449,749
Medicare patients
1,273
Services billed
5,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban184$162,691
EntrestoSacubitril/Valsartan123$116,018
Repatha SureclickEvolocumab89$47,867
JardianceEmpagliflozin52$45,633
FarxigaDapagliflozin Propanediol45$37,316
XareltoRivaroxaban39$29,756
CorlanorIvabradine Hcl13$6,331
Metoprolol Succinate390$4,127
Atorvastatin Calcium439$3,158
ClopidogrelClopidogrel Bisulfate310$2,795
Ezetimibe172$2,722
Rosuvastatin Calcium268$2,320
Olmesartan Medoxomil142$2,185
Spironolactone220$1,438
SotalolSotalol Hcl64$1,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$499$162,691184 claims
NovartisEntresto$189$116,018123 claims
Boehringer IngelheimJardiance$508$45,63352 claims
AstraZenecaFarxiga$835$37,31645 claims
Johnson & JohnsonXarelto$566$29,75639 claims
AmgenCorlanor$254$6,33113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Corinth

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →